Program
SYH2069
A development code. Also written as “SYH2069 Injection”, “SYH2069 Injection (group 1)” and “SYH2069 Injection (group 2)”.
Its studies are mostly in Obesity · Diabetes Mellitus, Type 2, led by CSPC Pharmaceutical Group.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| CSPC Pharmaceutical Group | 33 open or running | phase 2since Aug 25, 2026 | Jul 14, 2026 | Sep 28, 2027phase 2 · NCT07796477 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 14, 2026First study: phase 1 study in OverweightFirst studyNCT07736391 · 104 enrolled · China
- Aug 25, 20262 phase 2 studiesPhase 2 reachedNCT07803991, NCT07796477
Ahead
- Sep 28, 2027Primary completion: phase 2 study in Diabetes Mellitus, Type 2NCT07796477
- Sep 30, 2027Primary completion: phase 2 study in OverweightNCT07803991
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07803991Overweight · China | 2 | Not yet recruiting | Sep 30, 2027 | 360 |
| NCT07796477Diabetes Mellitus, Type 2 · China | 2 | Not yet recruiting | Sep 28, 2027 | 240 |
| NCT07736391Overweight · China | 1 | Active, not recruiting | Jul 30, 2026 | 104 |
How it is read
Names in the registry
- “SYH2069 Injection”, 2 entries
- “SYH2069 Injection (group 1)”, 1 entry
- “SYH2069 Injection (group 2)”, 1 entry
- “SYH2069 Injection (group 3)”, 1 entry
- “SYH2069 Injection (group 4)”, 1 entry
Codes read as this program: SYH2069.
Conditions, from the studies’ own filings
- Obesity, 2 studies
- Diabetes Mellitus, Type 2, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.